Oncotelic Therapeutics Inc (OTLC)

$0.09 0.00 (-2.51%)
Market Cap 41.67M
Revenue (ttm) 0.00
Net Income (ttm) -4.52M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 1.83
Volume 146,100
Avg Vol 340,480
Day's Range N/A - N/A
Shares Out 439.09M
Stochastic %K 24%
Beta -0.67
Analysts Strong Buy
Price Target $4.00

Company Profile

Oncotelic Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of drugs for the treatment of orphan oncology indications. It develops antisense and small molecule injectable drugs for the treatment of cancer. The company is also developing OXi4503 for the treatment of acute myeloid leukemia and myelodysplastic syndromes; OT-101, an antisense against TGF-ß2, which is in phase 3 clinical trials for pancreatic cancer and glioblastoma, as well as for the treatme...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 635 7000
Fax: 650 635 7001
Address:
29397 Agoura Road, Suite 107, Agoura Hills, United States
Dingo2
Dingo2 Nov. 12 at 3:10 PM
$OTLC that .10 is still a stickler. Waiting for the push
0 · Reply
NetworkNewsWire
NetworkNewsWire Nov. 11 at 8:03 PM
NetworkNewsBreaks – $OTLC and Sapu Bioscience Publish Landmark Review Defining Sub-15 nm Nanoparticles as New Frontier in Drug Delivery https://ibn.fm/F7Rg7
0 · Reply
Techallure
Techallure Nov. 11 at 1:42 PM
$OTLC Sooner or later some big AI platformers will require the AI engine that is mapping all TGFB2 protein pathway responses Be prepared
0 · Reply
Techallure
Techallure Nov. 8 at 4:43 PM
$OTLC published Nov 8, 2025 https://www.mdpi.com/1422-0067/26/22/10842 Be prepared
1 · Reply
Techallure
Techallure Nov. 8 at 4:41 PM
$OTLC Sub-15 nm Nanoparticles for Drug Delivery: Emerging Frontiers and Therapeutic Potential by Tapas De 1,*, Vuong Trieu 1, Scott Myers 1, Sanjive Qazi 1, Saran Saund 2 and Cynthia Lee 2 1 Oncotelic Therapeutics, 29397 Agoura Road, Suite #107, Agoura Hills, CA 91301, USA 2 Sapu Bioscience, 10840 Thornmint Road, Suite #118, San Diego, CA 92127, USA * Author to whom correspondence should be addressed. Int. J. Mol. Sci. 2025, 26(22), 10842; https://doi.org/10.3390/ijms262210842 (registering DOI) Submission received: 18 September 2025 / Revised: 18 October 2025 / Accepted: 22 October 2025 / Published: 8 November 2025
0 · Reply
NetworkNewsWire
NetworkNewsWire Nov. 7 at 8:37 PM
InvestorNewsBreaks – $OTLC Venture Begins Clinical Trials of Innovative Cancer Therapy https://ibn.fm/BDN4N
0 · Reply
Techallure
Techallure Nov. 7 at 8:21 PM
$OTLC Who hits .33 first? $OTLC or $RDGL ? Will come down to a photo finish …and both break out from the pack
1 · Reply
Think_Bigly
Think_Bigly Nov. 4 at 6:15 PM
$OTLC https://www.futuremarketinsights.com/reports/pancreatic-cancer-market
0 · Reply
Dingo2
Dingo2 Nov. 4 at 3:22 PM
$OTLC well, looking better above .10! Maintaining above would be nice, blow up to a much higher level would be 👌
0 · Reply
ckruel
ckruel Nov. 3 at 9:41 PM
$OTLC Locked ad loaded"…….
1 · Reply
Latest News on OTLC
No data available.
Dingo2
Dingo2 Nov. 12 at 3:10 PM
$OTLC that .10 is still a stickler. Waiting for the push
0 · Reply
NetworkNewsWire
NetworkNewsWire Nov. 11 at 8:03 PM
NetworkNewsBreaks – $OTLC and Sapu Bioscience Publish Landmark Review Defining Sub-15 nm Nanoparticles as New Frontier in Drug Delivery https://ibn.fm/F7Rg7
0 · Reply
Techallure
Techallure Nov. 11 at 1:42 PM
$OTLC Sooner or later some big AI platformers will require the AI engine that is mapping all TGFB2 protein pathway responses Be prepared
0 · Reply
Techallure
Techallure Nov. 8 at 4:43 PM
$OTLC published Nov 8, 2025 https://www.mdpi.com/1422-0067/26/22/10842 Be prepared
1 · Reply
Techallure
Techallure Nov. 8 at 4:41 PM
$OTLC Sub-15 nm Nanoparticles for Drug Delivery: Emerging Frontiers and Therapeutic Potential by Tapas De 1,*, Vuong Trieu 1, Scott Myers 1, Sanjive Qazi 1, Saran Saund 2 and Cynthia Lee 2 1 Oncotelic Therapeutics, 29397 Agoura Road, Suite #107, Agoura Hills, CA 91301, USA 2 Sapu Bioscience, 10840 Thornmint Road, Suite #118, San Diego, CA 92127, USA * Author to whom correspondence should be addressed. Int. J. Mol. Sci. 2025, 26(22), 10842; https://doi.org/10.3390/ijms262210842 (registering DOI) Submission received: 18 September 2025 / Revised: 18 October 2025 / Accepted: 22 October 2025 / Published: 8 November 2025
0 · Reply
NetworkNewsWire
NetworkNewsWire Nov. 7 at 8:37 PM
InvestorNewsBreaks – $OTLC Venture Begins Clinical Trials of Innovative Cancer Therapy https://ibn.fm/BDN4N
0 · Reply
Techallure
Techallure Nov. 7 at 8:21 PM
$OTLC Who hits .33 first? $OTLC or $RDGL ? Will come down to a photo finish …and both break out from the pack
1 · Reply
Think_Bigly
Think_Bigly Nov. 4 at 6:15 PM
$OTLC https://www.futuremarketinsights.com/reports/pancreatic-cancer-market
0 · Reply
Dingo2
Dingo2 Nov. 4 at 3:22 PM
$OTLC well, looking better above .10! Maintaining above would be nice, blow up to a much higher level would be 👌
0 · Reply
ckruel
ckruel Nov. 3 at 9:41 PM
$OTLC Locked ad loaded"…….
1 · Reply
NetworkNewsWire
NetworkNewsWire Nov. 3 at 5:51 PM
Sapu Nano Reveals the Initial In-Human Clinical Trial of Sapu-003, Intravenous Everolimus (Afinitor(R)) at Australian Translational Breast Cancer Symposium $OTLC https://ibn.fm/Av6bM
0 · Reply
Dingo2
Dingo2 Nov. 3 at 5:31 PM
$OTLC me seeing that damn .10 ceiling and waiting for the melt up!
0 · Reply
NetworkNewsWire
NetworkNewsWire Oct. 31 at 7:42 PM
BioMedNewsBreaks – $OTLC to Present Sapu003 Data at 2025 San Antonio Breast Cancer Symposium https://ibn.fm/I3QOx
0 · Reply
NetworkNewsWire
NetworkNewsWire Oct. 30 at 3:49 PM
NetworkNewsBreaks – $OTLC Featured in NetworkNewsWire Editorial on Nanomedicine Advances https://nnw.fm/F5U3f
0 · Reply
NetworkNewsWire
NetworkNewsWire Oct. 29 at 1:07 PM
Nanomedicine Innovations Transforming Oncology Drug Delivery and Bioavailability $OTLC $IOVA $MRK $LLY $JNJ https://ibn.fm/VF6qk
0 · Reply
Techallure
Techallure Oct. 28 at 7:07 PM
$OTLC A treatment combo that does not simply work well but rather a pipeline that helps many other FDA already approved drugs work well … Well, Big Pharma has no choice but to buy $$$
1 · Reply
NetworkNewsWire
NetworkNewsWire Oct. 28 at 4:41 PM
BioMedNewsBreaks — $OTLC Featured in NetworkNewsWire Editorial on Nanomedicine Innovations in Oncology https://ibn.fm/LCIUu
0 · Reply
Dingo2
Dingo2 Oct. 28 at 3:49 PM
$OTLC really, still stalled at the.10 line in the sand? That needs erased and moved up to the next level 😐
1 · Reply
NetworkNewsWire
NetworkNewsWire Oct. 27 at 1:10 PM
Nanomedicine Breakthrough Technology Redefining Drug Delivery, Bioavailability in Oncology $OTLC $IOBT $NVS $BCAX $PFE https://ibn.fm/3BZ5O
0 · Reply
Techallure
Techallure Oct. 24 at 10:43 AM
$OTLC The abstracts collectively detail the clinical rationale, molecular biomarkers, and pharmacokinetic data supporting the ongoing Phase 1 trial in HR⁺/HER2⁻ metastatic breast cancer. Well everyone should go study up on FDA approved “surrogate biomarkers” and with these surrogate biomarkers, clinical trials can be shortened … quickly stopped and approved all based upon surrogate biomarkers. Enjoy
1 · Reply
NetworkNewsWire
NetworkNewsWire Oct. 23 at 7:53 PM
InvestorNewsBreaks – $OTLC Announces Three Accepted Abstracts on Deciparticle (TM) Everolimus (Sapu003) at 2025 San Antonio Breast Cancer Symposium https://ibn.fm/Elcsq
0 · Reply
aj_
aj_ Oct. 23 at 2:17 PM
$OTLC goes up 0.000234 at a time and drops 2 cents in 4 seconds.
0 · Reply